

**Doramectin Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 24.02.2025
6.0	14.04.2025	5191222-00018	Date of first issue: 22.10.2019

---

**SECTION 1: Identification of the substance/mixture and of the company/undertaking****1.1 Product identifier**

Trade name : Doramectin Formulation

**1.2 Relevant identified uses of the substance or mixture and uses advised against**Use of the Sub-  
stance/Mixture : Veterinary productRecommended restrictions  
on use : Not applicable**1.3 Details of the supplier of the safety data sheet**Company : MSD  
20 Spartan Road  
1619 Spartan, South Africa

Telephone : +27119239300

E-mail address of person  
responsible for the SDS : EHSDATASTEWARD@msd.com**1.4 Emergency telephone number**

+1-908-423-6000

---

**SECTION 2: Hazards identification****2.1 Classification of the substance or mixture****Classification (REGULATION (EC) No 1272/2008)**

Reproductive toxicity, Category 1B	H360D: May damage the unborn child.
Specific target organ toxicity - single exposure, Category 2	H371: May cause damage to organs.
Specific target organ toxicity - repeated exposure, Category 2	H373: May cause damage to organs through prolonged or repeated exposure.
Short-term (acute) aquatic hazard, Category 1	H400: Very toxic to aquatic life.
Long-term (chronic) aquatic hazard, Category 1	H410: Very toxic to aquatic life with long lasting effects.

**2.2 Label elements****Labelling (REGULATION (EC) No 1272/2008)**

Hazard pictograms :



## Doramectin Formulation

Version 6.0      Revision Date: 14.04.2025      SDS Number: 5191222-00018      Date of last issue: 24.02.2025  
Date of first issue: 22.10.2019

Signal word : Danger

Hazard statements : H360D May damage the unborn child.  
H371 May cause damage to organs.  
H373 May cause damage to organs through prolonged or repeated exposure.  
H410 Very toxic to aquatic life with long lasting effects.

Precautionary statements : **Prevention:**  
P201 Obtain special instructions before use.  
P264 Wash skin thoroughly after handling.  
P273 Avoid release to the environment.  
P280 Wear protective gloves/ protective clothing/ eye protection/ face protection.

**Response:**  
P308 + P311 IF exposed or concerned: Call a POISON CENTER/ doctor.  
P391 Collect spillage.

Hazardous components which must be listed on the label:

Doramectin

## 2.3 Other hazards

This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

## SECTION 3: Composition/information on ingredients

## 3.2 Mixtures

## Components

Chemical name	CAS-No. EC-No. Index-No. Registration number	Classification	Concentration (% w/w)
Doramectin	117704-25-3	Acute Tox. 2; H300 Repr. 1B; H360D STOT SE 1; H370 (Central nervous system) STOT RE 1; H372 (Central nervous system, Liver, Kidney) Aquatic Acute 1; H400 Aquatic Chronic 1; H410	$\geq 1 - < 2,5$

## Doramectin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 24.02.2025
6.0	14.04.2025	5191222-00018	Date of first issue: 22.10.2019

		M-Factor (Chronic aquatic toxicity): 10.000	
--	--	--	--

For explanation of abbreviations see section 16.

### SECTION 4: First aid measures

#### 4.1 Description of first aid measures

- |                            |   |   |
|----------------------------|---|---|
| General advice             | : | In the case of accident or if you feel unwell, seek medical advice immediately.<br>When symptoms persist or in all cases of doubt seek medical advice.  |
| Protection of first-aiders | : | First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).   |
| If inhaled                 | : | If inhaled, remove to fresh air.<br>Get medical attention.  |
| In case of skin contact    | : | In case of contact, immediately flush skin with soap and plenty of water.<br>Remove contaminated clothing and shoes.<br>Get medical attention.<br>Wash clothing before reuse.<br>Thoroughly clean shoes before reuse. |
| In case of eye contact     | : | Flush eyes with water as a precaution.<br>Get medical attention if irritation develops and persists.  |
| If swallowed               | : | If swallowed, DO NOT induce vomiting.<br>Get medical attention.<br>Rinse mouth thoroughly with water.<br>Never give anything by mouth to an unconscious person.   |

#### 4.2 Most important symptoms and effects, both acute and delayed

- |       |   |   |
|-------|---|---|
| Risks | : | May damage the unborn child.<br>May cause damage to organs.<br>May cause damage to organs through prolonged or repeated exposure. |
|-------|---|---|

#### 4.3 Indication of any immediate medical attention and special treatment needed

- |           |   |   |
|-----------|---|---|
| Treatment | : | Treat symptomatically and supportively. |
|-----------|---|---|

### SECTION 5: Firefighting measures

#### 5.1 Extinguishing media

- |                              |   |                                       |
|------------------------------|---|---------------------------------------|
| Suitable extinguishing media | : | Water spray<br>Alcohol-resistant foam |
|------------------------------|---|---------------------------------------|

**Doramectin Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 24.02.2025
6.0	14.04.2025	5191222-00018	Date of first issue: 22.10.2019

---

Carbon dioxide (CO<sub>2</sub>)  
Dry chemical

Unsuitable extinguishing media : None known.

**5.2 Special hazards arising from the substance or mixture**

Specific hazards during fire-fighting : Exposure to combustion products may be a hazard to health.

Hazardous combustion products : Carbon oxides

**5.3 Advice for firefighters**

Special protective equipment for firefighters : In the event of fire, wear self-contained breathing apparatus. Use personal protective equipment.

Specific extinguishing methods : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.  
Use water spray to cool unopened containers.  
Remove undamaged containers from fire area if it is safe to do so.  
Evacuate area.

---

**SECTION 6: Accidental release measures****6.1 Personal precautions, protective equipment and emergency procedures**

Personal precautions : Use personal protective equipment.  
Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

**6.2 Environmental precautions**

Environmental precautions : Avoid release to the environment.  
Prevent further leakage or spillage if safe to do so.  
Prevent spreading over a wide area (e.g. by containment or oil barriers).  
Retain and dispose of contaminated wash water.  
Local authorities should be advised if significant spillages cannot be contained.

**6.3 Methods and material for containment and cleaning up**

Methods for cleaning up : Soak up with inert absorbent material.  
For large spills, provide dyking or other appropriate containment to keep material from spreading. If dyked material can be pumped, store recovered material in appropriate container.  
Clean up remaining materials from spill with suitable absorbent.  
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.

**Doramectin Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 24.02.2025
6.0	14.04.2025	5191222-00018	Date of first issue: 22.10.2019

Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

**6.4 Reference to other sections**

See sections: 7, 8, 11, 12 and 13.

**SECTION 7: Handling and storage****7.1 Precautions for safe handling**

- |                         |   |  |
|-------------------------|---|--|
| Technical measures      | : | See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.  |
| Local/Total ventilation | : | If sufficient ventilation is unavailable, use with local exhaust ventilation.  |
| Advice on safe handling | : | Do not get on skin or clothing.<br>Do not breathe mist or vapours.<br>Do not swallow.<br>Avoid contact with eyes.<br>Wash skin thoroughly after handling.<br>Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment<br>Keep container tightly closed.<br>Do not eat, drink or smoke when using this product.<br>Take care to prevent spills, waste and minimize release to the environment.                              |
| Hygiene measures        | : | If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use.<br>The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls. |

**7.2 Conditions for safe storage, including any incompatibilities**

- |   |   |  |
|---|---|--|
| Requirements for storage areas and containers | : | Keep in properly labelled containers. Store locked up. Keep tightly closed. Store in accordance with the particular national regulations.                      |
| Advice on common storage                      | : | Do not store with the following product types:<br>Strong oxidizing agents<br>Self-reactive substances and mixtures<br>Organic peroxides<br>Explosives<br>Gases |

**7.3 Specific end use(s)**

- |                 |   |                   |
|-----------------|---|-------------------|
| Specific use(s) | : | No data available |
|-----------------|---|-------------------|

## Doramectin Formulation

Version 6.0      Revision Date: 14.04.2025      SDS Number: 5191222-00018      Date of last issue: 24.02.2025  
 Date of first issue: 22.10.2019

### SECTION 8: Exposure controls/personal protection

#### 8.1 Control parameters

##### Occupational Exposure Limits

Components	CAS-No.	Value type (Form of exposure)	Control parameters	Basis
Doramectin	117704-25-3	TWA	35 µg/m <sup>3</sup> (OEB 3)	Internal
	Further information: Skin			
		Wipe limit	350 µg/100 cm <sup>2</sup>	Internal

#### 8.2 Exposure controls

##### Engineering measures

Use appropriate engineering controls and manufacturing technologies to control airborne concentrations (e.g., drip-less quick connections).

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.

Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face containment devices).

Minimize open handling.

##### Personal protective equipment

Eye/face protection	:	Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.
Hand protection	:	
Material	:	Chemical-resistant gloves
Remarks	:	Consider double gloving.
Skin and body protection	:	Work uniform or laboratory coat. Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces. Use appropriate degowning techniques to remove potentially contaminated clothing.
Respiratory protection	:	If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.
Filter type	:	Particulates type (P)

### SECTION 9: Physical and chemical properties

#### 9.1 Information on basic physical and chemical properties

Appearance	:	oily
Colour	:	light yellow
Odour	:	characteristic

**Doramectin Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 24.02.2025
6.0	14.04.2025	5191222-00018	Date of first issue: 22.10.2019

---

Odour Threshold	:	No data available
pH	:	No data available
Melting point/freezing point	:	-7 °C
Initial boiling point and boiling range	:	270 °C
Flash point	:	215,7 °C
Evaporation rate	:	No data available
Flammability (solid, gas)	:	Not applicable
Flammability (liquids)	:	Not applicable
Upper explosion limit / Upper flammability limit	:	No data available
Lower explosion limit / Lower flammability limit	:	No data available
Vapour pressure	:	No data available
Relative vapour density	:	No data available
Relative density	:	0,89 - 91
Density	:	No data available
Solubility(ies)		
Water solubility	:	practically insoluble
Partition coefficient: n-octanol/water	:	Not applicable
Auto-ignition temperature	:	No data available
Decomposition temperature	:	No data available
Viscosity		
Viscosity, kinematic	:	31,7 - 32,1 m2/s (25 °C)
Explosive properties	:	Not explosive
Oxidizing properties	:	The substance or mixture is not classified as oxidizing.

**9.2 Other information**

Molecular weight	:	No data available
Particle size	:	Not applicable

**Doramectin Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 24.02.2025
6.0	14.04.2025	5191222-00018	Date of first issue: 22.10.2019

**SECTION 10: Stability and reactivity****10.1 Reactivity**

Not classified as a reactivity hazard.

**10.2 Chemical stability**

Stable under normal conditions.

**10.3 Possibility of hazardous reactions**

Hazardous reactions : Can react with strong oxidizing agents.

**10.4 Conditions to avoid**

Conditions to avoid : None known.

**10.5 Incompatible materials**

Materials to avoid : Oxidizing agents

**10.6 Hazardous decomposition products**

No hazardous decomposition products are known.

**SECTION 11: Toxicological information****11.1 Information on toxicological effects**

Information on likely routes of exposure : Inhalation  
Skin contact  
Ingestion  
Eye contact

**Acute toxicity**

|| Not classified based on available information.

**Product:**

Acute oral toxicity : Acute toxicity estimate: > 2.000 mg/kg  
Method: Calculation method

**Components:****Doramectin:**

|| Acute oral toxicity : LD50 (Rat): 500 mg/kg  
Target Organs: Central nervous system  
  
LD50 (Mouse): > 2.000 mg/kg  
Target Organs: Central nervous system  
  
LD50 (Rat): 50 mg/kg  
Target Organs: Central nervous system  
  
LD50 (Mouse): 75 mg/kg  
Target Organs: Central nervous system  
  
|| Acute toxicity (other routes of : LD50 (Rat): > 300 mg/kg



## Doramectin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 24.02.2025
6.0	14.04.2025	5191222-00018	Date of first issue: 22.10.2019

administration)	Application Route: Intraperitoneal
	Target Organs: Central nervous system

**Skin corrosion/irritation**

Not classified based on available information.

**Serious eye damage/eye irritation**

Not classified based on available information.

**Respiratory or skin sensitisation****Skin sensitisation**

Not classified based on available information.

**Respiratory sensitisation**

Not classified based on available information.

**Germ cell mutagenicity**

Not classified based on available information.

**Components:****Doramectin:**

Genotoxicity in vitro	:	Test Type: Ames test Result: negative
		Test Type: Mouse Lymphoma Result: negative
		Test Type: unscheduled DNA synthesis assay Result: negative
Genotoxicity in vivo	:	Test Type: Micronucleus test Species: Mouse Result: negative
Germ cell mutagenicity- Assessment	:	Weight of evidence does not support classification as a germ cell mutagen.

**Carcinogenicity**

Not classified based on available information.

**Components:****Doramectin:**

Carcinogenicity - Assessment	:	Weight of evidence does not support classification as a carcinogen
------------------------------	---	--

**Reproductive toxicity**

May damage the unborn child.

**Components:****Doramectin:**

Effects on foetal development	:	Test Type: Embryo-foetal development
-------------------------------	---	--------------------------------------

## Doramectin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 24.02.2025
6.0	14.04.2025	5191222-00018	Date of first issue: 22.10.2019

ment

Species: Rat  
 Application Route: Oral  
 Embryo-foetal toxicity: NOAEL: 0,3 mg/kg body weight  
 Symptoms: Reduced body weight

Test Type: Embryo-foetal development  
 Species: Mouse  
 Application Route: Oral  
 Embryo-foetal toxicity: NOAEL: 3 mg/kg body weight  
 Symptoms: Embryolethal effects

Test Type: Embryo-foetal development  
 Species: Rabbit  
 Application Route: Oral  
 General Toxicity Maternal: NOAEL: 0,75 mg/kg body weight  
 Symptoms: Maternal effects, Embryotoxic effects.

Reproductive toxicity - Assessment : Clear evidence of adverse effects on development, based on animal experiments.

**STOT - single exposure**

May cause damage to organs.

**Components:****Doramectin:**

Exposure routes : Oral  
 Target Organs : Central nervous system  
 Assessment : Shown to produce significant health effects in animals at concentrations of 300 mg/kg bw or less.

**STOT - repeated exposure**

May cause damage to organs through prolonged or repeated exposure.

**Components:****Doramectin:**

Exposure routes : Oral  
 Target Organs : Central nervous system, Liver, Kidney  
 Assessment : Shown to produce significant health effects in animals at concentrations of 10 mg/kg bw or less.

**Repeated dose toxicity****Components:****Doramectin:**

Species : Rat  
 LOAEL : 30 mg/kg  
 Application Route : Oral  
 Exposure time : 3 Months  
 Target Organs : Central nervous system

Species : Rat

## Doramectin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 24.02.2025
6.0	14.04.2025	5191222-00018	Date of first issue: 22.10.2019

---

NOAEL	: 2 mg/kg
Application Route	: Oral
Exposure time	: 3 Months
Target Organs	: Central nervous system, Liver, Kidney

Species	: Dog
NOAEL	: 2 mg/kg
Application Route	: Oral
Exposure time	: 36 d
Target Organs	: Eye
Symptoms	: Dilatation of the pupil

Species	: Dog
NOAEL	: 0,1 mg/kg
Application Route	: Oral
Exposure time	: 92 d
Target Organs	: Central nervous system, Eye
Symptoms	: Dilatation of the pupil

**Aspiration toxicity**

Not classified based on available information.

**Experience with human exposure****Components:****Doramectin:**

Skin contact	: Target Organs: Gastro-intestinal system Symptoms: Nausea, Diarrhoea Target Organs: Central nervous system Symptoms: Dizziness, Headache Target Organs: Eye Symptoms: Irritation Target Organs: Skin Symptoms: Irritation Target Organs: Respiratory system Symptoms: Breathing difficulties
Ingestion	: Target Organs: Gastro-intestinal system Symptoms: Nausea, Abdominal pain, Diarrhoea Target Organs: Central nervous system Symptoms: Dizziness

**SECTION 12: Ecological information****12.1 Toxicity****Components:****Doramectin:**

Toxicity to fish	: LC50 (Lepomis macrochirus (Bluegill sunfish)): 11 µg/l Exposure time: 96 h Method: OECD Test Guideline 203  LC50 (Oncorhynchus mykiss (rainbow trout)): 5,1 µg/l Exposure time: 96 h
------------------	---

**Doramectin Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 24.02.2025
6.0	14.04.2025	5191222-00018	Date of first issue: 22.10.2019

	Method: OECD Test Guideline 203
Toxicity to daphnia and other aquatic invertebrates	: EC50 (Daphnia magna (Water flea)): 0,1 µg/l Exposure time: 48 h Method: OECD Test Guideline 202
M-Factor (Chronic aquatic toxicity)	: 10.000

**Ecotoxicology Assessment**

Acute aquatic toxicity	: Very toxic to aquatic life.
------------------------	-------------------------------

**12.2 Persistence and degradability**

No data available

**12.3 Bioaccumulative potential****Components:****Doramectin:**

Bioaccumulation	: Species: Lepomis macrochirus (Bluegill sunfish) Bioconcentration factor (BCF): 71 Method: OECD Test Guideline 305
Partition coefficient: n-octanol/water	: log Pow: 4,5 pH: 7

**12.4 Mobility in soil****Components:****Doramectin:**

Distribution among environmental compartments	: log Koc: 4,94
---	-----------------

**12.5 Results of PBT and vPvB assessment****Product:**

Assessment	: This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.
------------	--

**Components:****Doramectin:**

Assessment	: Substance is not very persistent and very bioaccumulative (vPvB).
------------	---

**12.6 Other adverse effects****Product:**

Endocrine disrupting potential	: The substance/mixture does not contain components considered to have endocrine disrupting properties according to
--------------------------------	---

## Doramectin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 24.02.2025
6.0	14.04.2025	5191222-00018	Date of first issue: 22.10.2019

REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

**SECTION 13: Disposal considerations****13.1 Waste treatment methods**

Product	:	Dispose of in accordance with local regulations. According to the European Waste Catalogue, Waste Codes are not product specific, but application specific. Waste codes should be assigned by the user, preferably in discussion with the waste disposal authorities. Do not dispose of waste into sewer.
Contaminated packaging	:	Empty containers should be taken to an approved waste handling site for recycling or disposal. If not otherwise specified: Dispose of as unused product.

**SECTION 14: Transport information****14.1 UN number**

ADN	:	UN 3082
ADR	:	UN 3082
RID	:	UN 3082
IMDG	:	UN 3082
IATA	:	UN 3082

**14.2 UN proper shipping name**

ADN	:	ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S. (Doramectin)
ADR	:	ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S. (Doramectin)
RID	:	ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S. (Doramectin)
IMDG	:	ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S. (Doramectin)
IATA	:	Environmentally hazardous substance, liquid, n.o.s. (Doramectin)

**14.3 Transport hazard class(es)**

	Class	Subsidiary risks
ADN	:	9
ADR	:	9

**Doramectin Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 24.02.2025
6.0	14.04.2025	5191222-00018	Date of first issue: 22.10.2019

---

**RID** : 9**IMDG** : 9**IATA** : 9**14.4 Packing group****ADN**

Packing group	: III
Classification Code	: M6
Hazard Identification Number	: 90
Labels	: 9

**ADR**

Packing group	: III
Classification Code	: M6
Hazard Identification Number	: 90
Labels	: 9
Tunnel restriction code	: (-)

**RID**

Packing group	: III
Classification Code	: M6
Hazard Identification Number	: 90
Labels	: 9

**IMDG**

Packing group	: III
Labels	: 9
EmS Code	: F-A, S-F

**IATA (Cargo)**

Packing instruction (cargo aircraft)	: 964
Packing instruction (LQ)	: Y964
Packing group	: III
Labels	: Miscellaneous

**IATA (Passenger)**

Packing instruction (passenger aircraft)	: 964
Packing instruction (LQ)	: Y964
Packing group	: III
Labels	: Miscellaneous

**14.5 Environmental hazards****ADN**

Environmentally hazardous	: yes
---------------------------	-------

**ADR**

Environmentally hazardous	: yes
---------------------------	-------

**RID**

Environmentally hazardous	: yes
---------------------------	-------

**IMDG**

Marine pollutant	: yes
------------------	-------

**IATA (Passenger)**

**Doramectin Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 24.02.2025
6.0	14.04.2025	5191222-00018	Date of first issue: 22.10.2019

Environmentally hazardous : yes

**IATA (Cargo)**

Environmentally hazardous : yes

**14.6 Special precautions for user**

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

**14.7 Transport in bulk according to Annex II of Marpol and the IBC Code**

Remarks : Not applicable for product as supplied.

**SECTION 15: Regulatory information****15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture**

The components of this product are reported in the following inventories:

AICS : not determined

DSL : not determined

IECSC : not determined

**15.2 Chemical safety assessment**

A Chemical Safety Assessment has not been carried out.

**SECTION 16: Other information**

Other information : Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

**Full text of H-Statements**

H300	: Fatal if swallowed.
H360D	: May damage the unborn child.
H370	: Causes damage to organs if swallowed.
H372	: Causes damage to organs through prolonged or repeated exposure if swallowed.
H400	: Very toxic to aquatic life.
H410	: Very toxic to aquatic life with long lasting effects.

**Full text of other abbreviations**

Acute Tox.	: Acute toxicity
Aquatic Acute	: Short-term (acute) aquatic hazard
Aquatic Chronic	: Long-term (chronic) aquatic hazard
Repr.	: Reproductive toxicity
STOT RE	: Specific target organ toxicity - repeated exposure
STOT SE	: Specific target organ toxicity - single exposure

ADN - European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways; ADR - Agreement concerning the International Carriage of Dangerous Goods by

## Doramectin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 24.02.2025
6.0	14.04.2025	5191222-00018	Date of first issue: 22.10.2019

Road; AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CLP - Classification Labelling Packaging Regulation; Regulation (EC) No 1272/2008; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECHA - European Chemicals Agency; EC-Number - European Community number; ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RID - Regulations concerning the International Carriage of Dangerous Goods by Rail; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; SVHC - Substance of very high concern; TCSI - Taiwan Chemical Substance Inventory; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative

**Further information**

Sources of key data used to compile the Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

**Classification of the mixture:**

Repr. 1B	H360D
STOT SE 2	H371
STOT RE 2	H373
Aquatic Acute 1	H400
Aquatic Chronic 1	H410

**Classification procedure:**

Calculation method
Calculation method
Calculation method
Calculation method
Calculation method

Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text.



## Doramectin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 24.02.2025
6.0	14.04.2025	5191222-00018	Date of first issue: 22.10.2019

---

Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

ZA / EN